solo per uso di ricerca
N. Cat.: S1103
Struttura chimica
| Target correlati | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Casein Kinase |
|---|---|
| Altro Aurora Kinase Inibitori | Hesperadin Barasertib-HQPA (AZD2811) Alisertib (MLN8237) Tozasertib (VX-680, MK-0457) MLN8054 Danusertib (PHA-739358) MK-5108 TCS7010 (Aurora A Inhibitor I) AMG-900 CCT137690 |
| Linee cellulari | Tipo di saggio | Concentrazione | Tempo di incubazione | Formulazione | Descrizione dell'attività | PMID |
|---|---|---|---|---|---|---|
| human EoL-1-cell | Growth inhibition assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50=0.18678 μM | ||||
| MCF7 cell | Proliferation assay | Antiproliferative activity against MCF7 cell line, IC50=0.198 μM | ||||
| human P12-ICHIKAWA cell | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50=0.22441 μM | ||||
| human KARPAS-45 cell | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=0.38128 μM | ||||
| human ES3 cell | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=0.4732 μM | ||||
| human ES8 cell | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50=0.49806 μM | ||||
| human TE-11 cell | Growth inhibition assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50=0.53703 μM | ||||
| human RS4-11 cell | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=0.5544 μM | ||||
| human MOLT-16 cell | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=0.60961 μM | ||||
| human RKO cell | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=0.70656 μM | ||||
| human MV-4-11 cell | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=0.7963 μM | ||||
| human SW954 cell | Growth inhibition assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50=0.83635 μM | ||||
| human BE-13 cell | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50=0.84418 μM | ||||
| human MOLT-4 cell | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=0.89978 μM | ||||
| human NBsusSR cell | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=0.91387 μM | ||||
| human H9 cell | Growth inhibition assay | Inhibition of human H9 cell growth in a cell viability assay, IC50=0.92979 μM | ||||
| human A172 cell | Growth inhibition assay | Inhibition of human A172 cell growth in a cell viability assay, IC50=0.98411 μM | ||||
| human ES5 cell | Growth inhibition assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50=1.00248 μM | ||||
| human SBC-1 cell | Growth inhibition assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=1.03928 μM | ||||
| human NCI-H209 cell | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=1.16602 μM | ||||
| human NKM-1 cell | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=1.16798 μM | ||||
| human NCI-H720 cell | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=1.20627 μM | ||||
| human KE-37 cell | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=1.21388 μM | ||||
| human SW48 cell | Growth inhibition assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50=1.23155 μM | ||||
| human IST-SL1 cell | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=1.31727 μM | ||||
| human SK-NEP-1 cell | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=1.36498 μM | ||||
| human NOMO-1 cell | Growth inhibition assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50=1.36725 μM | ||||
| human DOHH-2 cell | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=1.40276 μM | ||||
| human ABC-1 cell | Growth inhibition assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50=1.40352 μM | ||||
| human Ramos-2G6-4C10 cell | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=1.40605 μM | ||||
| human EM-2 cell | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=1.41721 μM | ||||
| human NB14 cell | Growth inhibition assay | Inhibition of human NB14 cell growth in a cell viability assay, IC50=1.55621 μM | ||||
| human MOLT-13 cell | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=1.56706 μM | ||||
| human ECC10 cell | Growth inhibition assay | Inhibition of human ECC10 cell growth in a cell viability assay, IC50=1.63353 μM | ||||
| human LK-2 cell | Growth inhibition assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50=1.64594 μM | ||||
| human CTB-1 cell | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=1.67082 μM | ||||
| human NCI-H1581 cell | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=1.6755 μM | ||||
| human COLO-800 cell | Growth inhibition assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50=1.70382 μM | ||||
| human NB7 cell | Growth inhibition assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50=1.75297 μM | ||||
| human LAMA-84 cell | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=1.7552 μM | ||||
| human HCT-116 cells | Growth inhibition assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50=1.80908 μM | ||||
| SK-UT-1 cell | Growth inhibition assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50=1.8153 μM | ||||
| human H4 cell | Growth inhibition assay | Inhibition of human H4 cell growth in a cell viability assay, IC50=1.81578 μM | ||||
| human CAL-51 cell | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=1.83845 μM | ||||
| human LoVo cells | Proliferation assay | 72 h | Antiproliferative activity against human LoVo cells after 72 hrs by MTT-based WST8 reagent assay, IC50=1.9 μM | |||
| human HN cell | Growth inhibition assay | Inhibition of human HN cell growth in a cell viability assay, IC50=1.9251 μM | ||||
| human L-363 cell | Growth inhibition assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50=1.9512 μM | ||||
| human NCI-H747 cell | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50=2.03353 μM | ||||
| human A498 cell | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50=2.3669 μM | ||||
| Clicca per visualizzare più dati sperimentali sulle linee cellulari | ||||||
| Peso molecolare | 513.59 | Formula | C29H31N5O4 |
Conservazione (Dalla data di ricezione) | |
|---|---|---|---|---|---|
| N. CAS | 331771-20-1 | Scarica SDF | Conservazione delle soluzioni stock |
|
|
| Sinonimi | N/A | Smiles | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OCCCN5CCOCC5 | ||
|
In vitro |
DMSO
: 103 mg/mL
(200.54 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)
Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)
Risultati del calcolo:
Concentrazione di lavoro: mg/ml;
Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.
Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.
| Caratteristiche |
An Aurora selective ATP-competitive inhibitor.
|
|---|---|
| Targets/IC50/Ki |
Aurora A
(Cell-free assay) 110 nM
Aurora B
(Cell-free assay) 130 nM
LCK
(Cell-free assay) 880 nM
Src
(Cell-free assay) 1.03 μM
MEK1
(Cell-free assay) 1.79 μM
|
| In vitro |
In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity. |
| Saggio chinasico |
Saggi chinasici in vitro
|
|
Le Aurora A e B ricombinanti sono espresse come proteine di fusione marcate con His6 N-terminale usando un sistema di espressione baculovirale. Aurora A è purificata mediante cromatografia di affinità usando agarosio Ni-NTA, e Aurora B è purificata mediante cromatografia a scambio ionico usando CM Sepharose Fast Flow. 1 ng di enzima ricombinante purificato viene aggiunto a un cocktail di reazione contenente 25 mM Tris-HCl, pH 7,5, 12,5 mM KCl, 2,5 mM NaF, 0,6 mM DTT, 6,25 mM MnCl2, 10 μM di substrato peptidico, 10 μM per Aurora A o 5 μM ATP per Aurora B, e 0,2 μCi γ-[33P]ATP (attività specifica ≥2.500 Ci/mmol), e quindi incubato a RT per 60 minuti. Le reazioni vengono interrotte dall'aggiunta di acido fosforico al 20%, e i prodotti vengono catturati su filtri di nitrocellulosa P30 e analizzati per l'incorporazione di 33P con un contatore BetaplateTM. Nessun enzima e nessun valore di controllo composto vengono utilizzati per determinare la concentrazione di ZM447439, che ha dato il 50% di inibizione dell'attività enzimatica. Ulteriori dettagli sono disponibili su richiesta a Nicholas Keen.
|
Riferimenti |
|
| Metodi | Biomarcatori | Immagini | PMID |
|---|---|---|---|
| Western blot | p53 / p21 / p-p38 / p38 pHistone H3 / CEM BubR1 / MAD2 / Cyclin B1 |
|
23759594 |
| Immunofluorescence | p21 p53 Aurora B / Survivin |
|
23759594 |